Actinium Pharmaceuticals, Inc.
ATNM
$1.31
-$0.0795-5.72%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | 80.00% | -10.00% | -92.14% |
| Total Revenue | -- | -- | 80.00% | -10.00% | -92.14% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 80.00% | -10.00% | -92.14% |
| SG&A Expenses | -9.41% | -21.99% | -24.38% | -10.29% | 11.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.00% | -14.81% | -3.25% | 23.14% | 48.01% |
| Operating Income | 18.87% | 14.96% | 3.33% | -23.22% | -52.24% |
| Income Before Tax | 21.66% | 18.40% | 8.02% | -19.33% | -47.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 21.66% | 18.40% | 8.02% | -19.33% | -47.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.66% | 18.40% | 8.02% | -19.33% | -47.86% |
| EBIT | 18.87% | 14.96% | 3.33% | -23.22% | -52.24% |
| EBITDA | 19.14% | 15.18% | 3.36% | -23.48% | -53.00% |
| EPS Basic | 30.75% | 26.95% | 15.77% | -10.92% | -35.91% |
| Normalized Basic EPS | 30.76% | 26.94% | 15.75% | -10.95% | -35.92% |
| EPS Diluted | 30.75% | 26.95% | 15.77% | -10.92% | -35.91% |
| Normalized Diluted EPS | 30.76% | 26.94% | 15.75% | -10.95% | -35.92% |
| Average Basic Shares Outstanding | 13.03% | 11.51% | 9.66% | 8.50% | 10.22% |
| Average Diluted Shares Outstanding | 13.03% | 11.51% | 9.66% | 8.50% | 10.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
